Loading stock data…
Elicio Therapeutics, Inc. (ELTX)
$4.00
After Hours$3.99-0.01 (-0.20%)· Last close Jun 29
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Elicio Therapeutics, Inc. in the Healthcare sector is trading at $4.00 with a market capitalization of $239M. Wall Street consensus targets $20.67 (3 analysts), implying a +416.7% move over the next 12 months. The stock is currently near its 52-week low of $2.66, remaining 58.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +416.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 23) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.60M↓ | -$8.84M↓ | -$8.04M↑ | -$9.68M↑ | -$10.74M |
| Net Income | -$11.82M↓ | -$7.72M↑ | -$10.08M↑ | -$10.56M↑ | -$11.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II cl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$239.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
2796.45%
Volume
Today's trading volume
452,837
Recent News
This Monthly Dividend Powerhouse Is Trading at a Bargain-Bin Valuation
EPR Properties offers income investors a rare combination: a 6.3% monthly dividend yield, a conservative 73% payout ratio, and diversified exposure to experiential real estate well beyond movie theatres, trading at just 10.7x FFO.
Stocks Settle Sharply Higher as US-Iran Peace Deal Spurs Optimism
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.65%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.92%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.06%. June E-mini S&P futures (ESM26 ) rose +1.68%, and June E-mini Nasdaq futures...
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Monday afternoon with the NYSE Healthcare Index decreasing 0.6% and
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints
Elicio Therapeutics said the randomized trial, called AMPLIFY-7P, of its experimental immunotherapy did not achieve the pre-specified primary endpoint in certain pancreatic cancer patients.
Top Midday Decliners
Elicio Therapeutics (ELTX) said Monday its Phase 2 clinical study evaluating the experimental pancre